HIV Vaccine

This is an HIV antibody with a yellow core and pink outer shell.
Targeting HIV broadly neutralizing antibody precursors with precision in humans.
A protective HIV vaccine will need to induce broadly neutralizing antibodies (bnAbs) in humans, but priming rare bnAb precursor B cells has been challenging. This study provides proof-of-concept for Env trimer-based GT approaches to activate bnAb precursors and induce affinity maturation on the…
Picture of antibodies.
HIV vaccine using mRNA-encoded nanoparticles showed to be safe and well-tolerated
The GW VRU participated in IAVI-G002 as a clinical site for a phase 1 human clinical trial. This study evaluated the safety and immunogenicity of mRNA-encoded nanoparticles as priming immunogens and first-boosting immunogens (IAVI-G002).
NIAID Marks HIV Vaccine Awareness Day 2024
NIAID observes HIV Vaccine Awareness Day
gwschool
Multi-stage HIV vaccine regimen shows promising results in Phase 1 clinical trial
Read more about the new hope found in Phase 1 clinical trials for the HIV vaccine.
Subscribe to HIV Vaccine